...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Phase 3 BETonMACE Trial is Now Completed. Cognition and CKD Sub-Study Results to be Announced Soon.

Free
Message: Effects of apabetalone on cognition

The CTAD Conference begins Wed Afternoon 12/4 and ends mid-day Sat 12/7 

Resverlogix has The 3rd and 4th time slots in a 45 minute session commencing at 4pm pst Thur 12/5

CTAD San Diego 2019 - Final program

Thursday, DECEMBER 5

4.00 p.m SYMPOSIUM 3 Epigenetics and the BET-system in vascular dementia, Alzheimer’s disease and mixed dementia – the problem and potential remedies Chairman: Bengt Winblad, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden

PRESENTER 1: Dementias, who and how to treat and by what specialty . Addressing problem and current and potential future therapeutic practices Charles DeCarli, MD, FAAN, FAHA, UC Davis, CA, USA

PRESENTER 2: Fluid biomarkers that predict and project brain health Henrik Zetterberg, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

PRESENTER 3: The epigenetic inhibitor APABETALONE corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease Ewelina Kulikowski, SVP Research and Development, Resverlogix Corporation, Calgary, Canada

PRESENTER 4: Epigenetics, the BET-system, Alzheimer’s Disease and Vascular Cognitive Impairment; The BETonMACE study and effects of apabetalone 100 mg b.i.d. two years treatment on cognition in diabetes patients with established cardiovascular disease Jeffrey Cummings, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Here is the link:

https://www.ctad-alzheimer.com/files/files/FINAL_PROGRAM_CTAD2019_au4nov.pdf

Dr Cummings will present the cognitive data from BETonMACE

This is going to take some time to unravel -not expecting an immediate market reaction to this -

another piece of the puzzle - adds value

Chicagoest

 

 

 

Share
New Message
Please login to post a reply